Rural Families Want to Own Their Source of Power

This summer, I swapped the European drizzle for the Indian Monsoons for my latest quarterly trip to the Mlinda office in Kolkata.

This visit focused on our activities in Purulia District, West Bengal. It is the newest location we have expanded into with our electrification project. Our electrical installations are in ‘tribal’ villages, by which is meant the members of the community are descendants of those who have lived there for centuries before them, experiencing little migration inwards or outwards, living off a local economy, with strong community ties and equally strong ties to the land. The 2001 census estimated “tribal” people to represent over 8% of the Indian population, more than 80 million people back in 2001. They have minimal access to communication, transport, financial, health and education services. If the Mlinda model works in this community, chances are our model could succeed anywhere in India, perhaps also beyond.

I was keen to visit Purulia as this sedentary lifestyle contrasts that of the Sundarbans, our other project location, where people are tied into the regional and national economy and where human settlement is recent, since the early 1900s, and still migrating in and out of the area in search of employment and trade. In contrast, Purulia is sedentary with modes of consumption and production that remain little changed for hundreds of years. I had questions about the community’s ability and willingness to accept the Mlinda electrification model. The answers I found challenge misconceptions of working with cash-poor, financially self-sufficient communities.

–          Q: Cut-off from inter-regional commerce seen in other rural areas, would households in Purulia have the cash to invest in communally owned solar mini-grids?

Although communities in Purulia have less spare cash than in the Sundarbans, they do have some and are willing to part with it for services they value. We had to tweak our model. At times up to thirteen households share ownership of a 225 watt installation, where each household pays a loan of 130 rupees (1.6€ or 2US$) a month for 6 years to access two light bulbs and a mobile phone charger, equivalent to the amount they spend on kerosene.

–          Q: Would they be interested in purchasing private solar-mini-grids in areas already defined as “electrified” according to State definitions?

In the Sundarbans we found that promises of electrification made by hopeful electioneering candidates in off-grid areas turned communities off buying solar power. In Purulia disillusionment with the grid was quite stark. We were not surprised to find high demand for solar electrification products in areas considered “already electrified”. We knew that an area is considered electrified by government standards even if only 10% of households are connected to the main grid. Even then, as many are already aware, being connected to the grid is no guarantee to accessing electricity.

This image shows the grid lines coexisting with the lines between the homes between which we have helped to install shared mini-grids. Though connected to the grid, the households we visited do not have any power and are keen to pay for it if access can be guaranteed, rather than pay for a public utility which does not provide a service.

–          Q: If Purulia’s economy is based on subsistence farming, what can Mlinda add that would help further reduce the carbon footprint of households that is already very low by any standard?

It turns out that even in a community with a small carbon footprint, we can play a role to help the community identify practices where green-house emissions can be reduced and goods with a positive impact promoted. In Purulia, within three months of introducing a different rice cultivation method, 47 plots had already converted to the “system of rice intensification”, a system developed in the 1960s widely praised for increasing rice yields while reducing the water use, green-house gas emissions from standing water, reliance on chemical fertilisers as well as pesticides.

We will be reporting more on this and other activities in future updates as we further refine our strategy to develop environmental stewardship, to encourage positive environmental impacts in production and consumption, beyond the benefits of electrification.


Important lessons to remember for now are 1) communities we may, from the outside, judge as poor and deserving only of charity hand-outs have a sense of ‘agency’ and control of the management of their resources, willing to pay and invest long term for services they value; 2) communities that already “electrified” are as deserving of solar electrification as those that are “off-grid” – and from an environmental perspective, perhaps more so as they compete with coal powered systems; 3) there is room for behaviour change interventions, or environmental stewardship activities, even in low-carbon economies.


Halozyme Therapeutics Provides An Update On Anticipated Milestones For 2015 At The

“Our progress in 2014 has set the stage for a meaningful 2015, a year in which we plan to further elucidate the potential of our cheap jerseys from china investigational new drug PEGPH20 in pancreatic and non small cell lung cancer (NSCLC) and anticipate a continued ramp in royalty revenues from our collaborative products with partners who utilize our ENHANZE technology,” stated Dr. Helen Torley, President cheap jerseys and Chief Executive Officer. “During the course of 2015, we anticipate expanding and accelerating our PEGPH20 clinical development efforts. commercialization of HYQVIA [(Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase)] continue to validate our proprietary ENHANZE technology. The growth in the number of approvals for ENHANZE products and the recent launch successes continue to garner interest from potential partners.”PEGPH20 in Combination with gemcitabine and ABRAXANE (Pancreatic Cancer Program)

Present Phase 1b (Study 201) results at ASCO GI (poster scheduled for January 16, 2015).

Complete patient enrollment in the on going Phase 2 multi center, randomized clinical trial (Study 202) evaluating PEGPH20 as a first line therapy for patients with stage IV metastatic pancreatic cancer, in the second half of 2015.

Initiate patient enrollment and dosing for a registration trial in the fourth quarter of 2015 or the first quarter of 2016, pending regulatory feedback.

PEGPH20 in Combination with docetaxel (NSCLC Program)

Complete patient enrollment in the on going global Phase 1b multi center, randomized clinical trial (PRIMAL) evaluating PEGPH20 as a second line therapy for patients with locally advanced or metastatic NSCLC in the third quarter of 2015, pending the number of dose escalation cohorts of PEGPH20.

The Phase 1b study will include both a dose escalation and dose expansion phase evaluating two different schedules.

Initiate patient enrollment and dosing for the Phase 2 randomized portion of the clinical trial following the evaluation of the Phase 1b data.

PEGPH20 in Combination with a PD 1 Inhibitor

Initiate a Phase 1b open label multicenter, randomized clinical trial evaluating PEGPH20 as a second line therapy for patients with locally advanced or metastatic NSCLC whose tumors accumulate high levels of HA, in the second half of 2015.

Collaboration Products ENHANZE is Halozyme’s proprietary drug delivery platform based on the Company’s patented recombinant human hyaluronidase enzyme (rHuPH20). Throughout 2015, Halozyme intends to provide support for ongoing launch activities for Herceptin SC, MabThera SC and HYQVIA, as well as support the efforts of our collaborative partners to develop wholesale nfl jerseys and apply ENHANZE technology to their respective targets.

2015 Financial Guidance The Company ended 2014 with approximately $135 wholesale jerseys million in cash, cash equivalents and marketable securities (these results are unaudited) and does not anticipate the need for dilutive financing to fund operations. For the full year 2015, the Company expects:

Net revenues to be in the range of $85 million to $95 million.

Operating expenses to be in the range of $145 million to $155 million.

Net cash burn to be between $35 million and $45 million.

About Halozyme Halozyme Therapeutics a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company’s research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme’s pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The Company has partnerships with Pfizer, Janssen and Baxter. Halozyme is headquartered in Diego, CA.

Safe Harbor Statement The statements above regarding our anticipated milestones and financial guidance for 2015, product development plans and goals, clinical trial expectations and results, anticipated regulatory approvals and partnered product plans and expectations are forward looking statements that involve risk and uncertainties that could cause actual results to differ materially from those in the forward looking statements. does not undertake to update its forward looking statements.Articles Connexes: